APA (7th ed.) Citation
(2026). Efficacy and Safety of Low‐Frequency Daratumumab Regimen in Systemic Light‐Chain Amyloidosis. Cancer Medicine.
Chicago Style (17th ed.) Citation
"Efficacy and Safety of Low‐Frequency Daratumumab Regimen in Systemic Light‐Chain Amyloidosis." Cancer Medicine 2026.
MLA (9th ed.) Citation
"Efficacy and Safety of Low‐Frequency Daratumumab Regimen in Systemic Light‐Chain Amyloidosis." Cancer Medicine, 2026.
Warning: These citations may not always be 100% accurate.